Compare
PRO DEX Inc vs Delcath Systems, Inc. vs NeuroPace Inc vs Anika Therapeutics, Inc.
| Latest fiscal year | PRO DEX Inc PDEX | Delcath Systems, Inc. DCTH | NeuroPace Inc NPCE | Anika Therapeutics, Inc. ANIK |
|---|---|---|---|---|
| Year ended | 2026-06-30 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $77.55M | $85.23M | $99.99M | $112.82M |
| Revenue growth (YoY) | +16.5% | +129.1% | +25.1% | -5.9% |
| Gross margin | 31.4% | 86.2% | 77.2% | 56.6% |
| Operating margin | 16.8% | 0.8% | -16.3% | -9.8% |
| Net margin | 17.6% | 3.2% | -21.5% | -9.6% |
| Net income | $13.66M | $2.70M | -$21.46M | -$10.88M |
| EPS (Diluted) | $4.12 | $0.07 | -$0.66 | -$0.76 |
| Operating cash flow | $7.24M | $22.52M | -$11.01M | $11.19M |
| Free cash flow | $6.76M | $20.97M | -$11.34M | $4.36M |
| Cash & equivalents | $8.19M | $43.45M | $21.69M | $57.48M |
| Total assets | $74.51M | $123.63M | $105.56M | $190.27M |
| Total liabilities | $26.88M | $12.41M | $86.53M | n/a |
| Shareholders' equity | $47.63M | $111.22M | $19.03M | $143.47M |
| Return on year-end equity | 28.7% | 2.4% | -112.8% | -7.6% |
| Shares outstanding | 3.19M | 34.69M | 33.57M | 13.89M |
Revenue, most recent five fiscal years
| Fiscal year | PRO DEX Inc | Delcath Systems, Inc. | NeuroPace Inc | Anika Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | $77.55M Ended 2026-06-30 | $85.23M Ended 2025-12-31 | $99.99M Ended 2025-12-31 | $112.82M Ended 2025-12-31 |
| 1 year earlier | $66.59M Ended 2025-06-30 | $37.20M Ended 2024-12-31 | $79.91M Ended 2024-12-31 | $119.91M Ended 2024-12-31 |
| 2 years earlier | $53.84M Ended 2024-06-30 | $2.06M Ended 2023-12-31 | $65.42M Ended 2023-12-31 | $120.79M Ended 2023-12-31 |
| 3 years earlier | $46.09M Ended 2023-06-30 | $2.72M Ended 2022-12-31 | $45.52M Ended 2022-12-31 | $113.83M Ended 2022-12-31 |
| 4 years earlier | $42.04M Ended 2022-06-30 | $3.56M Ended 2021-12-31 | $45.18M Ended 2021-12-31 | $147.79M Ended 2021-12-31 |